Galecto Biotech AB: Clinical Trials

2 active not recruiting, 2 completed, 2 unknown, 1 withdrawn. 7 Phase 2, 4 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	7	Active not recruiting 2, Completed 2, Unknown 2, Withdrawn 1
Phase 1	4	Unknown 2, Completed 1, Withdrawn 1

Follow Galecto Biotech AB: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma GB1211, Pembrolizumab, Placebo - Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma	Phase 2	Active not recruiting	Providence Health & Services	12	2024-02-29	2026-09-22
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). GB1211, Placebo, Atezolizumab - Non-Small Cell Lung Cancer	Phase 1 / Phase 2	Unknown	Galecto Biotech AB	88	2022-03-15	2024-04-12
A Single and Repeat Dose Trial in Participants With Hepatic Impairment GB1211, Placebo - Hepatic Impairment	Phase 1 / Phase 2	Unknown	Galecto Biotech AB	54	2021-09-09	2023-05-11
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis GB2064 - Myelofibrosis	Phase 2	Active not recruiting	Galecto Biotech AB	21	2021-06-09	2024-04-03
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis GB1211, Placebo - Non-alcoholic Steatohepatitis (NASH)	Phase 1 / Phase 2	Withdrawn	Galecto Biotech AB		2021-03-01	2021-02-04
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) GB0139, Placebo - Idiopathic Pulmonary Fibrosis (IPF)	Phase 2	Completed	Galecto Biotech AB	172	2019-02-19	2024-05-22
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Inhaled TD139, Placebo - Idiopathic Pulmonary Fibrosis	Phase 1 / Phase 2	Completed	Galecto Biotech AB	60	2014-09-01	2023-11-07

Conditions studied

Idiopathic Pulmonary Fibrosis (2)  ·  Liver Cirrhosis (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Melanoma (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Primary Myelofibrosis (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Interventions

GB-0139 (1)  ·  atezolizumab (1)  ·  pembrolizumab (1)

Countries

United States (3)  ·  Australia (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Poland (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Georgia (1)  ·  Ireland (1)  ·  Israel (1)  ·  Russia (1)

Top investigators

Brendan D. Curti, MD (1)  ·  Francois Ghiringhelli, MD (1)  ·  Michael Charlton, MD (1)  ·  Richard F Schlenk, MD (1)  ·  Toby Maher, MD (1)  ·  Toby Maher, MD, PhD (1)  ·  Zahariy Krastev, MD (1)

Results publications

PMID 33072090, PMID 33214209, PMID 35120836, PMID 39358661

NIH funding

2018 (1)